Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Heptares Therapeutics Limited
Heptares Therapeutics Limited Biopark

Heptares Therapeutics Limited patents


Recent patent applications related to Heptares Therapeutics Limited. Heptares Therapeutics Limited is listed as an Agent/Assignee. Note: Heptares Therapeutics Limited may have other listings under different names/spellings. We're not affiliated with Heptares Therapeutics Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "H" | Heptares Therapeutics Limited-related inventors


 new patent  Pharmaceutical compounds

wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.... Heptares Therapeutics Limited

Mutant g-protein coupled receptors and methods for selecting them

The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the... Heptares Therapeutics Limited

Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor

This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula. (I) where... Heptares Therapeutics Limited

Muscarinic agonists

or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.... Heptares Therapeutics Limited

Cgrp receptor antagonists

wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.... Heptares Therapeutics Limited

Cgrp receptor antagonists

wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.... Heptares Therapeutics Limited

1,2,4-triazine-4-amine derivatives

According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A21, or, particularly, the A2, receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or... Heptares Therapeutics Limited

4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators

The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.... Heptares Therapeutics Limited

Bicyclic aza compounds as muscarinic m1 receptor antagonists

This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R1-R5,... Heptares Therapeutics Limited

Cgrp receptor antagonists

wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.... Heptares Therapeutics Limited

Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula... Heptares Therapeutics Limited

Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists

The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia,... Heptares Therapeutics Limited

Muscarinic m1 receptor agonists

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is... Heptares Therapeutics Limited

Mutant g-protein coupled receptor proteins and methods for producing them

A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a Class 1 parent GPCR, wherein (i) the one or more mutations are located within a window... Heptares Therapeutics Limited

Cgrp receptor antagonists

wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.... Heptares Therapeutics Limited

Orexin receptor antagonists

wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.... Heptares Therapeutics Limited

Cgrp receptor antagonists

wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.... Heptares Therapeutics Limited

Cgrp receptor antagonists

wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.... Heptares Therapeutics Limited

Muscarinic receptor agonists

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q,... Heptares Therapeutics Limited

Muscarinic agonists

or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.... Heptares Therapeutics Limited

Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula... Heptares Therapeutics Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Heptares Therapeutics Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Heptares Therapeutics Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###